grant
Elucidate the landscape of druggable targets for eliminating cancer persister cells
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Apr 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY2025AI basedAI based modelAI modelAffectAssayBioassayBiological AssayC-K-RASCRISPR interferenceCRISPR-dCas9-mediated repressionCRISPR/dCas9 interferenceCRISPR/dCas9-mediated transcriptional inhibitionCRISPRiCancer ModelCancerModelCancersCell BodyCell Communication and SignalingCell Culture TechniquesCell SignalingCellsClinicalClustered Regularly Interspaced Short Palindromic Repeats interferenceCombined Modality TherapyComplexDNA seqDNA sequencingDNAseqDataDetectable Residual DiseaseDoseDrug TargetingDrug TherapyDrug ToleranceDrugsEnvironmentGeneralized GrowthGeneticGoalsGrowthHypoxiaHypoxicIFN-GammaIFN-gIFN-γIFNGIFNγImmune InterferonInterferon GammaInterferon Type IIIntracellular Communication and SignalingK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS2KRAS2 geneKi-RASLibrariesMalignant CellMalignant NeoplasmsMalignant TumorMedicationMinimal Residual DiseaseModelingMultimodal TherapyMultimodal TreatmentNSCLCNSCLC - Non-Small Cell Lung CancerNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOncogene K-RasOxygen DeficiencyPatientsPatternPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPopulationPublishingRASK2Recurrent NeoplasmRecurrent diseaseRecurrent tumorRelapsed DiseaseResearch ResourcesResearch SpecimenResidual NeoplasmResidual TumorsResistanceResourcesSignal TransductionSignal Transduction SystemsSignalingSourceSpecimenStress TestsSurvey InstrumentSurveysTestingTimeTissue GrowthTumor BiologyValidationWorkXenograft Modelartificial intelligence basedartificial intelligence modelartificial intelligence-based modelbiological signal transductioncancer cellcancer progressioncell culturecell culturescombination therapycombined modality treatmentcombined treatmentcomparativedata resourcedesigndesigningdrug interventiondrug treatmentdrug/agentdruggable targetgenetic resistancegenome scalegenome-widegenomewideimprovedknowledge baseknowledge databaselFN-Gammamalignancymulti-modal therapymulti-modal treatmentmultidisciplinarymutantneoplasm progressionneoplasm recurrenceneoplasm/cancerneoplastic progressionnon-geneticnongeneticnovelontogenypharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspre-clinicalpreclinicalpressurepreventpreventingrational designrepressing CRISPR-dCas9 systemresidual diseaseresistance mutationresistantresistant mutationresponsescreeningscreeningssmall moleculesuccesstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttooltreatment strategytumortumor progressionv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologvalidation studiesvalidationsxenograft transplant modelxenotransplant model
Description preview
PROJECT SUMMARY
Residual disease, caused by incomplete killing of cancer cell populations, is a critical limitation of targeted
therapy, and almost inevitability leads to tumor recurrence. A growing body of evidence suggests a significant
contribution of persister cells to residual disease. Persister cells are small subpopulations of the original…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click